BREAKING
Home » Posts Tagged "VLA15"

Lyme Disease Vaccine Candidate to enter Phase 3 Study

By

NewsDesk @bactiman63 Pfizer Inc. and Valneva SE announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy,...

ticks

Lyme disease vaccine candidate: Valneva and Pfizer report more positive Phase 2 data

By

NewsDesk @bactiman63 On Friday, Valneva and Pfizer reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed...

Lyme disease vaccine candidate VLA15: More positive Phase 2 results, including booster response reported

By

By NewsDesk  @infectiousdiseasenews Vaccine company, Valneva and Pfizer today announced further positive Phase 2 results, including booster response, for Lyme disease vaccine candidate VLA15. The Phase...

Lyme Disease vaccine candidate: Final Phase 2 study initiated

By

Valneva SE and Pfizer Inc. announced Monday the initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is anticipated to be the...

Lyme disease vaccine: Valneva reports positive second Phase 2 data

By

By NewsDesk  @bactiman63 Specialty vaccine company, Valneva, today announced positive initial results for its second Phase 2 study (VLA15-202) of Lyme disease vaccine candidate VLA15. Compared to study...

Lyme disease vaccine: Valneva announces positive initial Phase 2 study results

By

 Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced positive initial results for its first Phase 2 study (VLA15-201) of Lyme disease vaccine...

Lyme disease vaccine: Valneva announces collaboration with Pfizer

By

Valneva SE, a specialty vaccine company, and Pfizer Inc. today announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical...

Lyme vaccine: Valneva completes recruitment for Phase 2 studies

By

Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, Monday announced that it has completed patient recruitment of the Phase 2 studies for...

Lyme disease vaccine candidate: Initiation of second study of Phase 2 clinical development

By

Biotech and vaccine development company, Valneva announced today the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15. The overall...

Lyme disease vaccine update: ‘Significant progress’ being made

By

In an update on the progress of  Valneva’s Lyme disease vaccine candidate VLA15, the company says they have successfully concluded the end of Phase 1 process for this candidate with the Food...